Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M95,969Revenue $M25,711Net Margin (%)9.9Z-Score2.5
Enterprise Value $M100,289EPS $2.0Operating Margin %14.4F-Score4
P/E(ttm))47.1Cash Flow Per Share $0Pre-tax Margin (%)12.7Higher ROA y-yN
Price/Book4.510-y EBITDA Growth Rate %10.5Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %-9.0Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-31.8ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.7Insider Buy (3m)0ROE % (ttm)11.0Less Shares Outstanding y-yN
Payout Ratio %174Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 76.015%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 76.015%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 76.015%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 76.015%Sold Out0
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 76.0118%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 76.0118%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 76.0118%New holding, 95518 sh.95,518
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 76.0118%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 76.0140%Reduce -40.32%106,975
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 76.0140%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 76.0151%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 76.0151%Reduce -81.87%68,000
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 76.0149%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 76.0149%Sold Out0
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 76.0160%Reduce -38.8%932,000
AZNCharles Brandes 2012-12-31 Buy 1.2%$44.34 - $48.9
($46.77)
$ 76.0162%New holding, 2188735 sh.2,188,735
AZNJohn Hussman 2012-12-31 Reduce-0.56%$44.34 - $48.9
($46.77)
$ 76.0162%Reduce -24.49%1,523,000
AZNDavid Dreman 2012-12-31 Reduce-0.2%$44.34 - $48.9
($46.77)
$ 76.0162%Reduce -52.4%152,504
AZNJoel Greenblatt 2012-12-31 Reduce-0.12%$44.34 - $48.9
($46.77)
$ 76.0162%Reduce -31.34%83,972
AZNJoel Greenblatt 2012-09-30 Add0.12%$44.91 - $48.35
($46.83)
$ 76.0162%Add 42.7%122,294
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-06-3040,40000.02New Buy
AZN George Soros 2014-06-30150,0000.010.08New Buy
AZN - CALLDaniel Loeb 2014-06-301,000,0000.080.91
AZN John Hussman 2014-06-30223,5000.021.3-1.97%
AZN David Dreman 2014-06-30117,8320.010.66-13%
AZN Charles Brandes 2014-06-30386,0580.030.35-71.06%
AZN Joel Greenblatt 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


      More From Other Websites
      Britain's FTSE creeps higher; Tesco slides on profit warning Aug 29 2014
      Hopes rise for AstraZeneca cancer drug with start of new trial Aug 29 2014
      3 Health Care Stocks Pushing The Sector Higher Aug 28 2014
      Are You Too Late To Buy Shares In AstraZeneca plc? Aug 28 2014
      Heart Disease To Cost UK £15bn In 2014 Aug 27 2014
      Pfizer and Merck Collaborate to Develop Lung Cancer Therapy Aug 27 2014
      Deutsche Bank Says Pfizer Has A Strong Financial Position And Attractive Pipeline Aug 27 2014
      Should you buy ISIS? No, not that one Aug 27 2014
      Roche Furthers Immunotherapy Program with SP142 Launch Aug 26 2014
      Merck, Pfizer Combining Drugs In Lung Cancer Study Aug 26 2014
      Warren Buffett throws weight behind Burger King deal Aug 26 2014
      Stock futures hold mild gains amid economic reports Aug 26 2014
      A New Pfizer Inc. Bid For AstraZeneca plc? Aug 26 2014
      The 4 Companies Teaming Up For A New Tool To Fight Cancer Aug 25 2014
      Roche to Boost Respiratory Product Lineup with InterMune Buy Aug 25 2014
      [video] Roche's $8.3 billion deal for InterMune Aug 25 2014
      Roche's InterMune Acquisition Underscores How It And Pfizer Are On Different M&A Paths Aug 24 2014
      Balfour Beatty: The fine line between boldness and foolishness Aug 23 2014
      Ampio Shares Fall as STEP Study on Ampion Gets Delayed Aug 22 2014
      AstraZeneca Updates on PLATO Study Investigation on Brilinta Aug 22 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK